Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell LymphomaMichael R. Bishop, Jason R. Westin, Michael Dickinson et al.|New England Journal of Medicine|2021Cited by 532
Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda StudyMichael Bishop, Jason R. Westin, Michael Dickinson et al.|Blood|2021Cited by 15
Bianca: Phase II, single-arm, global trial to determine efficacy and safety of tisagenlecleucel in pediatric/young adult (YA) patients (Pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).Véronique Minard‐Colin, Birgit Burkhardt, Cristina Díaz de Heredia et al.|Journal of Clinical Oncology|2020Cited by 6
S255: EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) MATURE B-CELL NON-HODGKIN LYMPHOMA (NHL): THE PHASE II BIANCA STUDYVéronique Minard‐Colin, Birgit Burkhardt, Jochen Buechner et al.|HemaSphere|2022Cited by 5